AbbVie prices new rheumatoid arthritis drug at $59,000 a year

AbbVie Inc has priced its new rheumatoid arthritis treatment at $59,000 a year after gaining U.S. approval on Friday, a big boost for the drugmaker struggling with rising competition for Humira, its blockbuster therapy for the same condition.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news